# A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

> **NCT06916078** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 33 (estimated)

## Conditions studied

- Liver Dysfunction
- Healthy

## Interventions

- **DRUG:** Lepodisiran

## Key facts

- **NCT ID:** NCT06916078
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-23
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916078, "A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06916078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*